Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Cantargia AB
Baylor Research Institute
Nektar Therapeutics
Pfizer
Bayer
Fudan University
AstraZeneca
Vanderbilt-Ingram Cancer Center
Alliance for Clinical Trials in Oncology
Columbia University
University of Washington
Russian Academy of Medical Sciences
Vanderbilt-Ingram Cancer Center
Fudan University
Fudan University